Resources from the same session
Scientific rationale for dual inhibition of VEGF and EGFR
Presenter: Nobuyuki Takakura
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us?
Presenter: Federico Cappuzzo
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast
Case study from the clinic – Potential patient profile and include sequencing and discuss with panel
Presenter: Chao-Hua Chiu
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast